-
Ann Rheum Dis: Clinical characteristics and prognosis of infection with new coronavirus in patients with rheumatism
Time of Update: 2020-05-29
The study was designed to explore differences in clinical performance and prognosis between rheumatism and non-rheumatic patients after contracting the 2019 coronavirus (COVID-19) a comparative c
-
Ann Rheum Dis: Adamu mono-resistance reduction in patients with long-term clinical remission of rheumatoid arthritis
Time of Update: 2020-05-29
The study was designed to explore a link between baseline disease activity in patients with persistently remission of rheumatoid arthritis (RA) and the reduction of Adamu monoantigens or acute seiz
-
Semin Arthritis Rheu: Characteristics and outcomes of patients with diseased macroblastitis in the eye
Time of Update: 2020-05-29
The study was designed to describe the characteristics and prognosis of patients with clottel arteritis (GCA)-related eye injuries at the time of diagnosis a retrospective single-center cohort st
-
NEJM: Ruxolitinib significantly reduces risk of acute graft anti-host disease after heterogeneous stem cell transplant
Time of Update: 2020-05-29
Acute graft anti-host disease (GVHD) is an important complication after allogeneic stem cell transplantation, and not all patients respond to standard treatment of glucocorticoids In phase II trial
-
J Rheumatol: Late Chronic Kidney Disease of Lupus nephritis
Time of Update: 2020-05-29
Advanced chronic kidney disease (CKD) increases the risk of developing end-stage renal disease (ESRD) The study was designed to determine the rate of lupus nephritis (LN) progression in ESRD and th
-
Ann Rheum Dis: A new and reliable overall ultrasound score for psoriasis arthritis (DACTOS)
Time of Update: 2020-05-29
Finger inflammation is one of the most typical characteristics of psoriasis arthritis (PsA), which has a high lifetime prevalence and is included in PsA clinical indicators Musculoskeletal Ultrasou
-
Semin Arthritis Rheu: Link between outdoor air pollution and risk of rheumatoid arthritis
Time of Update: 2020-05-29
Air pollution is one of the high risk factors for the global burden of disease The relationship between air pollution and rheumatoid arthritis (RA) remains controversial This systematic evaluation
-
Aurinia completes FDA new drug application for treatment of lupus nephritis
Time of Update: 2020-05-29
Aurinia Pharmaceuticals announced the completion of its voclosporin application to the U.S Food and Drug Administration for a new drug (NDA) as a potential treatment for lupus nephritis (LN), a sev
-
J Rheumatol: Kidney Resistance Index, a new biomarker for vascular change in follow-up systemic sclerosis
Time of Update: 2020-05-29
This retrospective observation study is designed to assess SSc disease Changes in the kidney resistance index (RRI) over time and during treatment and associated with complications of the disease
-
T-cell therapy DSG3-CAART fda edited fast-track: for the treatment of common mucosal blisters
Time of Update: 2020-05-29
Cabaletta is a clinical-stage biotechnology company dedicated to the development of T-cell therapies for autoimmune diseases The U.S Food and Drug Administration (FDA) has granted fast-track certif
-
Pfizer's Mertoviline generic Ruxience, approved by the European Union
Time of Update: 2020-05-29
Pfizer has received EU approval for the biosimilar Ruxience (rituximab) biosimilar to CD20 monomera (rituxira, mabThera, rituximab) approved for the use of Ruxience for the treatment of non-Hodgk
-
Ann Rheum Dis: General Assessment of Physicians' Impact of Systemic Lupus Disease Activity (PGA)
Time of Update: 2020-05-29
The study was designed to assess the impact of laboratory test results on the overall assessment (PGA) scores of active physicians for systemic lupus disease sent 50 clinical cases to a group of
-
"Drug King" Adamu single resistance to the fierce rivals: biosimilar AVT02 achieved positive results
Time of Update: 2020-05-29
Alvotech Pharmaceuticals announced today that two studies on AVT02 have reached its main goal The AVT02 is a biosimilar of Humira (Adamu mono-resistant) with a high concentration (100mg/mL) dosage
-
J Rheumatol: High prevalence of lupus comorbidities in patients with psoriasis arthritis
Time of Update: 2020-05-29
The study was designed to assess the prevalence of lupus (SLE) in psoriasis arthritis (PsA) and to compare it with the general population using a database of large health care providers study ana
-
J Rheumatol: Liver abnormalities in patients with psoriasis arthritis
Time of Update: 2020-05-29
The purpose of this study was to determine the prevalence and incidence of liver abnormalities in patients with psoriasis arthritis (PsA) and to identify the factors associated with it researcher
-
Stocktaking: Lancet Research Selections, March 21, 2020
Time of Update: 2020-05-29
The of moisturizing cannot reduce the risk of neonatal eczema DOI : https://doi.org/10.1016/S0140-6736 (19) 32984-8 study found that skin barrier dysfunction predates the onset of eczema ev
-
Ann Rheum Dis: Reactive arthritis and other musculoskeletal symptoms associated with infection with e. coli (DEC)
Time of Update: 2020-05-29
The study used a forward-looking design to assess the association between infection with e coli (DEC) and reactive arthritis (ReA) and other reactive musculoskeletal (MSK) symptoms in international
-
Ann Rheum Dis: Phase II Trial of Kanamono Anti-Still Disease in Adults
Time of Update: 2020-05-29
Inhibition interleukin (IL)-1 is a promising treatment option for adult Still disease (AOSD) explored the efficacy and safety of carnamono in patients with a stressed AOSD in active joints throug
-
Incyte's JAK1/JAK2 inhibitor ruxolitinib cream treats atopic dermatitis in phase II clinical success
Time of Update: 2020-05-29
Incyte's JAK1/JAK2 inhibitor ruxolitinib's local cream struck the primary and secondary endpoints of the Stage III TRuE-AD1 trial in adolescents and adults with mild to moderate asymptomatic dermat
-
Stocktaking: A selection of Lancet Research on April 4, 2020
Time of Update: 2020-05-29
Guselkumab for active psoriasis arthritis (DISCOVER-1 study ) DOI: https://doi.org/10.1016/S0140-6736 (20) 30265-8 many psoriasis patients are not responding adequately to tumor necrosis fact
